"Immunotherapy, Adoptive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
Descriptor ID |
D016219
|
MeSH Number(s) |
E02.095.465.425.400.330.050.400 E05.478.550.520.050.400
|
Concept/Terms |
Immunotherapy, Adoptive- Immunotherapy, Adoptive
- Immunotherapy, Adoptive Cellular
- Adoptive Immunotherapy
- Adoptive Immunotherapies
- Immunotherapies, Adoptive
- Cellular Immunotherapy, Adoptive
- Adoptive Cellular Immunotherapies
- Cellular Immunotherapies, Adoptive
- Immunotherapies, Adoptive Cellular
- Adoptive Cellular Immunotherapy
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy, Adoptive".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy, Adoptive".
This graph shows the total number of publications written about "Immunotherapy, Adoptive" by people in this website by year, and whether "Immunotherapy, Adoptive" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 2 | 2 |
1997 | 1 | 0 | 1 |
1999 | 1 | 0 | 1 |
2001 | 1 | 0 | 1 |
2002 | 0 | 3 | 3 |
2003 | 2 | 4 | 6 |
2004 | 2 | 4 | 6 |
2005 | 1 | 1 | 2 |
2006 | 2 | 2 | 4 |
2007 | 1 | 1 | 2 |
2008 | 1 | 2 | 3 |
2010 | 4 | 2 | 6 |
2011 | 1 | 1 | 2 |
2012 | 3 | 2 | 5 |
2013 | 5 | 0 | 5 |
2014 | 3 | 1 | 4 |
2015 | 4 | 2 | 6 |
2016 | 1 | 0 | 1 |
2017 | 1 | 0 | 1 |
2018 | 3 | 1 | 4 |
2019 | 5 | 0 | 5 |
2020 | 3 | 1 | 4 |
2021 | 11 | 2 | 13 |
2022 | 1 | 11 | 12 |
2023 | 2 | 10 | 12 |
2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy, Adoptive" by people in Profiles.
-
Maybe you can't drive this CAR? Blood Adv. 2024 Feb 27; 8(4):1030-1031.
-
Engineering Challenges and Opportunities in Autologous Cellular Cancer Immunotherapy. J Immunol. 2024 01 15; 212(2):188-198.
-
If They RECUR, You Should Refer: A Community Oncologist Patient ID Roundtable Summary. Transplant Cell Ther. 2024 Jan; 30(1):14-16.
-
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023 10; 29(10):2570-2576.
-
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma. Blood Adv. 2023 09 26; 7(18):5579-5585.
-
Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL. Clin Lymphoma Myeloma Leuk. 2024 Feb; 24(2):83-93.
-
Infectious complications of car T-cell therapy: A longitudinal risk model. Transpl Infect Dis. 2023 Nov; 25 Suppl 1:e14148.
-
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions. Blood Adv. 2023 08 22; 7(16):4528-4538.
-
Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy. Blood Adv. 2023 07 11; 7(13):3192-3198.
-
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. N Engl J Med. 2023 Jul 13; 389(2):148-157.